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Summary: Molecular rapid diagnostic testing (mRDT) in bloodstream infections significantly
decreased the risk of mortality overall and with stewardship but not without. Time to effective
therapy, as well as length of stay, were decreased with mRDT.
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Background: Previous reports on molecular rapid diagnostic testing (mRDT) do not
consistently demonstrate improved clinical outcomes in bloodstream infections (BSIs). This
meta-analysis seeks to evaluate the impact of mRDT in improving clinical outcomes in BSIs.
Methods: We searched PubMed, CINAHL, Web of science, and EMBASE through May 2016
for BSI studies comparing clinical outcomes by mRDT and conventional microbiology methods.
Results: Thirty-one studies were included with 5,920 patients. Risk of morality was significantly
lower with mRDT as compared to conventional microbiology methods (OR 0.66, 95% CI 0.540.80) yielding a NNT of 20. The risk of mortality was slightly lower with mRDT in studies with
antimicrobial stewardship programs (ASPs) (OR 0.64, 95% CI 0.51-0.79) and non-ASP studies
failed to demonstrate a significant decrease in risk of mortality (OR 0.72, 95% CI 0.46-1.12).
Significant decreases in mortality risk were observed with both Gram-positive (OR 0.73, 95% CI
0.55-0.97) and Gram-negative organisms (OR 0.51, 95% CI 0.33-0.78) but not yeast (OR 0.90,
95% CI 0.49-1.67). Time to effective therapy decreased by a weighted mean difference of -5.03
hours (95% CI -8.60 to -1.45) and length of stay decreased by -2.48 days (95% CI -3.90 to 1.06).
Conclusions: For BSIs, mRDT was associated with significant decreases in risk of mortality in
the presence of a ASP, but not in its absence. Additionally, mRDT decreased time to effective
therapy and length of stay. mRDT should be considered as part of the standard of care in
patients with BSIs.
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Background
Bloodstream infections (BSIs) are associated with significant morbidity, mortality, and increased
length of stay (LOS) [1,2]. Delayed administration of effective antibiotics increases the risk of
mortality and therefore correct selection of an antibiotic regimen early in the treatment process
is paramount [3,4]. Delayed identification of the causative organism and culture susceptibilities
may often be responsible for delays in optimal antimicrobial therapy. Molecular rapid diagnostic
testing (mRDT), which includes tests such as polymerase chain reaction (PCR), matrix-assisted
laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), and peptide
nucleic acid fluorescent in situ hybridization (PNA-FISH), has improved upon conventional
microbiological methods, reducing time to organism identification, optimizing antimicrobial
therapy, and subsequently improving clinical outcomes, including mortality [5].

Advancement of RDT is now one of five overarching goals from the National Action Plan for
Combating Antibiotic-Resistant Bacteria [6]. Additionally, the 2016 Infectious Diseases Society
of America (IDSA) antimicrobial stewardship program (ASP) guidelines recommend the use of
rapid diagnostic testing with ASP support and intervention as an addition to conventional
methods for blood specimens to improve clinical outcomes [7]. Widespread implementation of
this technology has been limited due to inadequate outcomes data and high costs [8]. A recent
meta-analysis included evaluations of the clinical benefits of molecular and phenotypic rapid
diagnostics in BSIs, but was limited by the time frame of the literature included, with the most
recent study being published in 2012 [9]. Additionally, the impact on LOS was not assessed,
nor was the effect on mortality according to ASP presence. The objective of this systematic
review and meta-analysis was to provide a comprehensive and up-to-date assessment of
mRDT on mortality, time to effective therapy, and LOS, when compared to conventional
microbiology methods in patients with BSIs.
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Methods
Literature Search
We searched PubMed, CINAHL, Web of Science, and Embase from inception to May 31, 2016
for BSI studies in English comparing clinical outcomes by mRDT and conventional microbiology
methods. The search query used was (bacteremia or “bloodstream infection”) AND
(spectrometry OR "Matrix assisted laser desorption/ionization" OR MALDI-TOF OR microarray
OR PCR OR "nucleic acid" OR PNA OR molecular OR "polymerase chain reaction") AND
("length of stay" OR mortality OR morbidity OR diagnosis OR outcome). Two authors (TTT and
JBM) searched the literature and performed article selection independently. Differences were
resolved through consensus involving a third author (KWM). A manual search of the included
articles’ references was conducted to identify additional relevant studies. Unpublished studies
were included through searching abstracts from IDWeek, Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC), and European Congress of Clinical
Microbiology and Infectious Diseases (ESCMID) from 2007 to 2015 using the keywords
bacteremia or bloodstream infection.

Study Selection
All studies evaluating the differences in clinical outcomes between mRDT, either for organism
identification and/or resistance mechanism detection, and conventional methods in BSIs were
eligible for inclusion. mRDT was defined as commercially available molecular tests that are able
to provide results in 24 hours or less. Studies were included if results were reported for clinical
outcomes of interest. Studies were excluded if they were non-English studies, evaluated
infections with mycobacterial, viral, or parasitic organisms, or if mRDT was utilized on negative
blood cultures or direct blood specimens (e.g. Septifast).
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Outcomes
Outcomes evaluated included overall mortality, mortality in studies with ASP, mortality by
organism, time to effective therapy, and LOS. Mortality was defined as all-cause 30-day or inhospital. Organism types were grouped by Gram positive, Gram negative, yeast, or if a
combination thereof, were termed multiple. Time to effective therapy was defined as the time
from either blood specimen obtainment or positive test to a therapy with in vitro activity against
the infecting organism. LOS was defined as total hospital or from culture (collection or
positivity) LOS among either survivors or all patients within the study. Studies were classified as
ASP studies if the authors reported infectious diseases physician or pharmacist review of
antimicrobial selection based upon culture or mRDT results.

Quality Assessments
Assessments of quality were made by two authors (TTT and JBM) using the Newcastle-Ottawa
Scale (NOS) [10] for observation studies and the Risk of Bias (ROB) tool for randomized
controlled trials (RCT) [11]. NOS evaluates for the selection of patients, comparability of
patients, and assessment of outcomes. The ROB tool assess whether there is a low, high, or
unclear level of bias based on five primary domains of bias in RCTs, including selection,
performance, detection, attrition, and reporting bias [12]. Differences in quality assessment
between the two authors were resolved through consensus involving a third author (KWM).

Data Extraction and Analysis
All meta-analyses were performed using Review Manager v.5.3. Mortality outcomes were
assessed using a random effects model to estimate pooled odds ratios (OR) and 95%
confidence intervals (CI) with Dersimonian and Laird weights [13]. To express the effect of
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testing in clinical terms, the number needed to treat (NNT) to prevent one death was calculated.
The effect of mRDT on time to effective therapy and LOS was evaluated using a random effects
model and reported as weighted mean difference and 95% CI. Medians and interquartile ranges
or ranges were converted to means and standard deviations according to Wan et al. [14].
Publication bias was assessed using funnel plots and Egger’s test. Heterogeneity between
studies was evaluated with the I2 estimation and Cochran Q test [12]. For heterogeneity testing,
P < .10 was considered significant as the Q test has low power. Random-effects univariate
meta-regressions were performed for covariates that had possible effects on an outcome and
were reported in ≥ 10 studies using the metaphor package in R v.3.2.3. This systematic
literature review and meta-analysis was conducted following the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Supplementary Table 1).

Results
The literature search resulted in 7,273 studies meeting the keyword criteria (Figure 1). After
removing duplicates, titles and abstracts were reviewed for 5,426 studies. Studies not related to
our search were removed yielding 40 studies for full text review. Full-text review identified 5
articles with data not relevant to our meta-analysis, 3 studies without clinical outcomes, 2
studies with mRDT in each comparison arm, and 2 studies that evaluated mRDT on blood
specimens in septic patients without positive cultures. Review of the references of the included
studies resulted in 4 additional studies being added to the meta-analysis. Data were extracted
from 31 studies with 5,920 patients as two studies [15,16] contained overlapping data.

Characteristics of the included studies are shown in Table 1. Only 6 studies (19.4%) [17–22]
were conducted outside of the United States. The majority of studies included (26/31, 83.9%)
were designed as pre- post-intervention quasi-experimental studies when initiating mRDT.
While most of the studies reporting study setting were academic medical centers, 2 included
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studies (6.5%) [23,24] were from community hospitals. Among studies reporting patient
population information, adult patients were the most common cohort studied (95.2%, 20/21).
Gram-positive organisms were the most frequently reported BSI type included, occurring in 17
studies (54.8%), followed by Gram-negative organisms with 7 studies (22.6%). Multiple
organism and yeast studies comprised the remainder with 5 (16.1%) and 2 studies (6.5%),
respectively.

Laboratory practices varied among studies, including mRDT technologies used, frequency of
testing, and reporting processes. PCR or other microarray technologies were most frequently
utilized (20/31, 64.5%), followed by PNA-FISH (6/31, 19.4%) and MALDI-TOF (4/31, 12.9%).
One study (3.2%) utilized both a nanotechnology microarray system and confirmatory MALDITOF [25]. A distinction of MALDI-TOF analysis from direct blood specimen vs overnight solid
media incubation was reported in 4 of 5 MALDI-TOF studies [15,24,26,35] with a single study
[26] reporting the latter method. Of the 19 studies reporting the frequency of laboratory sample
testing, 5 studies (26.3%) reported real-time testing, 10 studies (52.6%) batch testing between 1
to 4 times daily, and 3 studies (15.8%) reported real-time testing during limited time frames (e.g.
7am-7pm). Among the 5 studies performing 24x7 real-time testing, mRDT result notifications
were reported as being performed in real time for two studies [27, 33] while another study [40]
only notified of the results and in real time if resistance genes were detected. Finally, notification
methods also varied between studies when reported, with the majority of the reporting studies
(17/29, 58.6%) reporting directly to the primary team or physician, while 3 studies (10.3%)
reported to the result to nurses.

ASP activities varied by study. The presence of an ASP facilitating mRDT represented the
majority of the data (20/31, 64.5%). In the 14 studies reporting ASP notification processes, only
half were 24x7 real-time. The remainder had set response hours (e.g., 8a-5p M-F) or once daily
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review of results. Two studies [23,27], which were both quasi-experimental, explicitly stated
whether the ASP was present in both periods with one [23] of the two having an ASP in the post
period only.

Clinical outcomes in BSIs generally favored mRDT over conventional microbiology (Figures 2
and 3). Among 26 studies [5,15,17–20,23,24,26,28–44], the odds of mortality were significantly
lower with mRDT (OR 0.66, 95% CI 0.54 to 0.80) yielding a NNT of 20. Stratification revealed
that the odds of mortality were significantly lower for BSIs using mRDT with ASP (OR 0.64, 95%
CI 0.51 to 0.79), but failed to achieve significance without ASP support (OR 0.72, 95% CI 0.46
to 1.12). Similar results were observed when a sensitivity analysis was performed using studies
[17,20,26,29,36,40,43] which controlled for confounding (Supplementary Figure 1). When
evaluating mortality by organism type (Figure 3), there was no significant difference in the odds
of mortality among yeast isolates (OR 0.90, 95% CI 0.49 to 1.67). In contrast, the odds of
mortality were reduced with mRDT among Gram-negative (OR 0.51, 95% CI 0.33 to 0.78),
Gram-positive (OR 0.73, 95% CI 0.55 to 0.97), and multiple organism testing (OR 0.58, 95% CI
0.32 to 1.04). Mortality in multiple organism testing had significant heterogeneity (Cochran’s Q P
= .07, I2 = 53%) due to a study [17] which used both mRDT and rapid susceptibility testing.
Exclusion of that study yielded a 51% decreased odds of mortality in multiple organism testing
(OR 0.49, 95% CI 0.33 to 0.71, Cochran’s Q P = .56, I2 = 0%). Sensitivity analysis using studies
[17,20,26,29,36,40,43] controlling for confounding achieved non-significant reductions in risk of
mortality by each organism group (Supplementary Figure 2). Meta-regressions of covariates by
the presence of an ASP (P = .56), organism type (P = .42), real-time ASP (P = .82), or real-time
mRDT (P = .34) as possible moderators for mortality were not significant.

Among 9 studies [20–22,25,26,33,34,37,44], time to effective therapy (Supplementary Figure 3)
was significantly decreased by a weighted mean difference of -5.03 hours (95% CI -8.60 to -
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1.45) with mRDT versus conventional microbiology. Time to effective therapy had significant
heterogeneity (Cochran’s Q P = .0002, I2 = 74%) due to a study [33] which was limited to
vancomycin resistant enterococci (VRE). Exclusion of that study yielded time to effective
therapy with a decreased weighted mean difference of -1.89 hours (95% CI -2.43 to -1.36,
Cochran’s Q P = .48, I2 = 0%). Evaluation of that study [33] and VRE subgroup data from 2
studies [25,36] yielded a time to effective therapy weighted mean difference of -26.65 h (95% CI
-35.43 to -17.88, Cochran’s Q P = .66, I2 = 0%). Finally, LOS (Supplementary Figure 4) was
significantly shorter with mRDT by -2.48 days (95% CI -3.90 to -1.06) and similar results were
observed among subgroups by total hospital LOS and from culture LOS. Sensitivity analysis
was performed using the only two studies [17,36] that controlled for confounding and reflected a
decreased LOS by a WMD of -8.08 days (-20.59 to 4.44, Cochran’s Q P < .0001, I2 = 95%).

Analysis of the potential for publication bias with funnel plots (Supplementary Figures 5-7)
suggested no evidence of publication bias for the analyses presented in Figures 2-3 and
Supplementary Figure 3. Similarly, Egger’s regression testing reflected an absence of
publication bias for the analyses presented in Figures 2, 3, and Supplementary Figure 3 (P =
.98, P = .98, P = .07, respectively). However, Egger’s regression testing suggested possible
publication bias with the LOS analysis (Supplementary Figure 4; P = .01).

Discussion
In this systematic review and meta-analysis of 31 studies and 5,920 BSI patients, mRDT was
associated with a decreased risk of mortality and LOS, as well as improved time to effective
therapy compared to conventional microbiological methods. The extent of adoption of mRDT for
BSIs among acute care facilities in the United States is unknown, although use of rapid
diagnostic tests for identification of drug resistant organisms and improving stewardship has
been called for by the National Action Plan for Combating Antibiotic-Resistant Bacteria [6].
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While a number of observational studies have supported the use of mRDT with ASPs for
improving clinical outcomes, a recent randomized control trial has suggested these technologies
have a limited impact [45]. However, it should be noted that the aforementioned study’s
definition of standard blood culture processing included MALDI-TOF, and therefore included
mRDT in both comparator groups.

Clinical implications with the use of rapid diagnostics in BSIs has been evaluated in one metaanalysis [9]. While the previous meta-analysis evaluated the use of RDT with communication of
results to providers, the role of ASP was not explored. Additionally, the meta-analysis was
limited by its literature review time frame and did not focus solely on molecular technologies. In
the current meta-analysis with 16 additional studies, we explored the relationship between
mRDT and ASP specifically. We found that mortality decreased significantly with mRDT in the
presence of ASP but not its absence. Thus, we believe our results support the IDSA ASP
guideline recommendation to utilize rapid diagnostics with ASP facilitation in BSIs [7]. Moreover,
our analysis approximates that mRDT would only need to be used in 20 patients with BSI in
order to prevent one death within 30 days, which further supports mRDT as the standard of care
in BSIs.

Compared to conventional microbiologic methods, mRDT was associated with significantly
decreased risk of mortality among gram-negative organisms, gram-positive organisms, and
multiple infection type studies, while yeast studies did not achieve significant mortality
reductions. However, among studies [17,20,26,29,36,40,43] controlling for confounding, nonstatistically significant reductions in risk of mortality were observed by organism groups. Failure
to demonstrate the benefit of mRDT in yeast BSIs on risk of mortality or among studies in the
sensitivity analysis may be due to the limited number of studies and corresponding sample
sizes.
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Detecting true mortality benefits may be difficult in pre-post studies that have not controlled for
confounding. Therefore, the use of an outcome more directly related to mRDT, such as time to
effective therapy, may be a better indicator of mRDT benefits. Despite few studies reported time
to effective therapy, we did observe a significant decrease in time to effective therapy. However,
the distribution of time to effective therapy varied both within and between studies. The
importance of time to effective therapy has been recently demonstrated in a study of VRE
bacteremia which reported a 3-fold increase in 30-day mortality in the absence of effective
therapy in the first 48h of BSI, and speculated that rapid diagnostics may be beneficial in
reducing time to effective therapy in the setting of VRE [3]. Our results suggest the particular
utility of mRDT in VRE BSIs, improving time to effective therapy by over 24 hours. Furthermore,
the mean time to effective therapy for all three VRE studies included in our analysis ranged from
43.7 hours to 50.2. As such, we believe mRDT may have profound benefits in patients with VRE
bacteremia, and may help minimize risk of mortality.

Finally, significant decreases in LOS were observed. While we did not evaluate costs, the
observed decreases in LOS have significant implications based on savings of cost per day for
hospitalization. A study evaluating the economic impact of mRDT in BSI demonstrated an
estimated $30,000 cost savings per 100 patients after accounting for mRDT costs [36].
However, the generalizability of decreased LOS reported are likely limited to large hospitals
and medical centers as only two of the included studies were community hospitals. Additionally,
LOS did not achieve significant reductions among the two studies [17,36] which controlled for
confounding, although the significant heterogeneity in this analysis and small sample limit
inference of these results.
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There are several limitations to this systematic review and meta-analysis. For LOS, our analysis
suggested possible publication bias. However, this may be related to the small number of
studies reporting this outcome. While the generalizability of our findings for clinical outcomes
may be limited to academic medical centers, it should be noted that two community hospital
studies were included [23,24]. In one of the community hospital studies, while an ASP was
present, non-ID trained pharmacists responded to the BSIs [24]. Future studies from the
community hospital setting elucidating outcomes would help to clarify best practices in this area.
Guidance for recording and reporting these outcomes when using RDT in BSIs has been
described and should be utilized by researchers in the future [9]. In addition, we treated all
interventions as equal with regards to technology type due to variability in laboratory practices
such as batching of assays or performing MALDI-TOF either directly from blood culture bottles
containing nutritional broth or from solid agar incubated overnight. Notification methods for
mRDT results also varied which could have implications on clinical outcomes. While future
evaluations may consider these variations and their relationship to clinical outcomes, our
analysis supports mRDT as a group improves outcomes in BSIs. Additionally, we believe the
implementation of mRDT should include an action plan to ensure correct interpretation, realtime reporting, and guidance on optimal therapy. Having 24x7 testing, with immediate
notifications to the provider along with direction from an ASP team, will facilitate the initiation,
escalation, or de-escalation of therapy in a meaningful timeframe.

Conclusion
mRDT was associated with significant decreases in morality in the presence of an ASP, but not
in its absence. Significant decreases in risk of mortality were also seen for gram-positive
organisms, gram-negative organisms, and multiple organism infection studies. Additionally,
mRDT was associated with decreased time to effective therapy and LOS. The greatest benefit
of mRDT for improving time to effective therapy may be for BSIs caused by resistant organisms,
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particularly VRE. Additional studies in community hospitals are needed, as are additional
studies elucidating the benefits of various microbiologic technologies in combination with ASP to
define best practices. Based on the clinical outcomes, mRDT should be considered as part of
the standard of care in patients with BSIs.
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Figure 1: Flow diagram.
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Figure 2: Mortality with mRDT vs conventional testing in BSI.

	
  
*Conference abstract. Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; ASP, antimicrobial
stewardship program; M-H, Mantel-Haenszel method; CI, confidence interval.	
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Figure 3: Mortality with mRDT vs conventional testing by organism type in BSI.	
  

	
  
*Conference abstract. Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; M-H, Mantel-Haenszel
method; CI, confidence interval.
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Table 1. Characteristics of Included Studies of Included in Systematic Review and Meta-analysis
Author
Year
Bauer [27]
2010
Beuving [17]
2015

Study
Design
Quasiexperimental
RCT

Setting
1150-bed
tertiary care
facility
750-bed
hospital

BSI Type

Laboratory
Tests

mRDT
Testing &
Notification
Recipient

ASP
Presence

ASP
Notification
Process

NOS
Score

82/74

S. aureus

Conventional
vs PCR

24x7;
Physician

Yes

Real-time
M-F 8a-5p

9

Adult

129/121

Multiple

Conventional
vs PCR

No

NA

NA

Adult

49/65

Gram-negative
organisms

Conventional
vs BC-GN

NR;
Physician
NR;
Physician &
ASP

Yes

NR

7

Adult

64/103

Gram-positive
organisms

Conventional
vs BC-GP

7a-7p;
Nurse

Yes

Real-time
7a-7p

7

Adult

49/48

Staphylococcus
spp.

Conventional
vs PCR

NR;
Physician

No

NA

9

Conventional
vs BC-GP

No

NA

8

Yes

Real-time

7

Yes

Real-time

9

Yes

Real-time

7

No

NA

9

Yes

Real-time

7

No

NA

9

Patient
Population

Sample Size,
mRDT/Control,
No. of Patients

Adult

Bias [28]
2015

Quasiexperimental

Box [23]
2015

Quasiexperimental

Cattoir [22]
2011

Quasiexperimental

Felsenstein [41]
2016

Quasiexperimental

Children’s
hospital

Pediatric

219/221

Gram-positive
organisms

Forrest [30]
2006

Quasiexperimental

Medical
center

NR

72/76

Yeast

Forrest [29]
2006

Case-control

NR

119/84

CoNS

Forrest [31]
2008

Quasiexperimental

Adult

95/129

Enterococcus
spp.

Frye [42]
2012

Quasiexperimental

Two 500bed medical
centers

Adult

110/134

Staphylococcus
spp.

Heil [32]
2012

Quasiexperimental

NR

Adult

21/61

Yeast

Holtzman [46]
2011

Quasiexperimental

Medical
center

Adult

99/100

CoNS

NR
5
Community
hospitals
900-bed
teaching
hospital

740-bed
medical
center
600-bed
teaching
hospital

Conventional
vs PNAFISH
Conventional
vs PNAFISH
Conventional
vs PNAFISH
Conventional
vs PCR
Conventional
vs PNAFISH
Conventional
vs PNAFISH

24x7 testing
but not realtime;
Physician
1x/day;
Team &
ASP
1x/day;
Team &
ASP
2x/day;
Physician &
ASP
2x/day M-F,
1x/day SS;
MRSA
results to
floor
7a-9:30p;
Physician &
PharmD
1x/day; EHR
only
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Table 1 continued.
Author
Year

Study
Design

Huang [26]
2013

Quasiexperimental

Lockwood [24]
2016

Quasiexperimental

Ly [43]
2008

RCT

Setting

Health
system
2
community
hospitals
907-bed
tertiary
care center

Patient
Population

Sample Size,
mRDT/Control,
No. of Patients

BSI Type

Adult

245/256

Multiple

Adult

241/149

Gram-negative
organisms

Adult

101/101

Staphylococcus
spp.

mRDT
Testing &
ASP
Notification Presence
Recipient
NR;
Conventional
Ordering
vs MALDIYes
clinician &
TOF
ASP
Conventional
NR; Nurse
vs MALDIYes
& ASP
TOF
Conventional
2x/day;
vs PNATreating
No
FISH
clinician
Conventional
NR; NR
Yes
vs PCR
24x7;
Conventional
Nurse and
Yes
vs PCR
PharmD
Conventional
NR; NR
No
vs PCR
1x/day MConventional
Sat; EHR
No
vs PCR
only
Conventional
NR;
vs MALDIPhysician
Yes
TOF
& ASP

Laboratory
Tests

ASP
Notification
Process

NOS
Score

6a-11:30p

9

Real-time

7

NA

NA

NR

7

Real-time
8a-5p M-F

7

NA

7

NA

7

6a-11:30p

7

Macvane [34]
2015

Quasiexperimental

NR

Adult

63/50

Gram-negative
organisms

Macvane [33]
2016

Quasiexperimental

709-bed
academic
center

Adult

23/45

Enterococcus
spp.

Maslonka [44]
2014

CaseControl

NR

NR

55/55

Multiple

Na [21]
2016

Quasiexperimental

Academic
hospital

NR

97/94

Staphylococcus
spp.

Nagel [35]
2014

Quasiexperimental

Health
system

Adult

117/129

CoNS

Neuberger [20]
2008

Quasiexperimental

NR

42/42

Klebsiella
pneumoniae

Conventional
vs PCR

11p-11a
M-F;
Physician

No

NA

9

Nguyen [47]
2010

Quasiexperimental

Adult

94/65

Staphylococcus
spp.

Conventional
vs PCR

NR; EHR
only

No

NA

9

Pardo [36]
2016

Case-control

Adult

84/252

Multiple

Conventional
vs PCR

1x/day;
ASP

Yes

NR

9

Tertiary
care
medical
center
Academic
hospital
939-bed
academic
medical
center
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Table 1 continued.

BSI Type

Laboratory
Tests

mRDT
Testing &
Notification
Recipient

ASP
Presence

ASP
Notification
Process

NOS
Score

107/112

Gram-negative
organisms

Conventional
vs MALDITOF

3-4x/day;
ASP

Yes

Real-time

9

Adult

95/133

Gram-positive
organisms

Conventional
vs BC-GP

NR;
Provider &
PharmD

Yes

NR

7

NR

74/65

Streptococcus /
Enterococcus
spp.

Conventional
vs BC-GP +
MALDI-TOF

NR;
PharmD

Yes

NR

7

NR

28/46

Enterococcus
spp.

Conventional
vs BC-GP

24x7; ASP

Yes

M-F 7:30a5p

7

Adult

67/59

Gram-negative
organisms

Conventional
vs BC-GN

24x7; ASP

Yes

Real-time

7

Multiple

Conventional
vs BCGP/GN

NR;
Hospital
physician
and ID
physician

Yes

NR

7

Setting

Patient
Population

Sample Size,
mRDT/Control,
No. of Patients

Quasiexperimental

1000-bed
quaternary
care
academic
hospital

Adult

Revolinksi [37]
2015

Quasiexperimental

NR

Roshdy [25]
2015

Quasiexperimental

Sango [38]
2013

Quasiexperimental

Sothoron [39]
2015

Quasiexperimental

NR

Quasiexperimental

413-bed
tertiary
medical
center

Author
Year

Study
Design

Perez [15]
2013

Suzuki [19]
2015

Academic
medical
center
695-bed
academic
medical
center

NR

88/147

401-bed
tertiary
24x7;
Walker [40]
Quasicare & 60Gram-negative Conventional
Physician
NR
97/98
Yes
Daily
9
2016
experimental
bed
organisms
vs BC-GN
if resistant
cancer
organism
hospitals
1200-bed
Wang [18]
Quasitertiary
Staphylococcus Conventional
1x/day;
NR
48/38
No
NA
7
2013
experimental
care
spp.
vs PCR
Physician
hospital
Note. MALDI-TOF, Matrix-Assisted Laser Desorption/Ionization Time-of-Flight; BC-GP, blood culture gram positive nanotechnology microarray system; BC-GN
blood culture gram negative nanotechnology microarray system; NR, not reported; NA, not applicable; NOS, Newcastle-Ottawa Scale; ROB, Risk of Bias; AST,
antibiotic susceptibility testing; EHR, electronic health record.
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Appendix
Supplementary Table 1: PRISMA Checklist
Section/topic
TITLE
Title
ABSTRACT
Structured
summary
INTRODUCTION
Rationale
Objectives
METHODS
Protocol and
registration
Eligibility criteria

#

Checklist item

1

Identify the report as a systematic review, meta-analysis, or both.

1

2

Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations;
conclusions and implications of key findings; systematic review registration number.

2

3
4

Describe the rationale for the review in the context of what is already known.
Provide an explicit statement of questions being addressed with reference to participants, interventions,
comparisons, outcomes, and study design (PICOS).

5

Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available,
provide registration information including registration number.
Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years
considered, language, publication status) used as criteria for eligibility, giving rationale.
Describe all information sources (e.g., databases with dates of coverage, contact with study authors to
identify additional studies) in the search and date last searched.
Present full electronic search strategy for at least one database, including any limits used, such that it could
be repeated.
State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if
applicable, included in the meta-analysis).
Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any
processes for obtaining and confirming data from investigators.
List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions
and simplifications made.
Describe methods used for assessing risk of bias of individual studies (including specification of whether this
was done at the study or outcome level), and how this information is to be used in any data synthesis.
State the principal summary measures (e.g., risk ratio, difference in means).
Describe the methods of handling data and combining results of studies, if done, including measures of
2
consistency (e.g., I ) for each meta-analysis.
Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias,
selective reporting within studies).

6

Information sources

7

Search

8

Study selection

9

Data collection
process
Data items

10

Risk of bias in
individual studies
Summary measures
Synthesis of results

12

Risk of bias across
studies

15

11

13
14

Reported on
page #

3
3
4
4
4
4
4-5
4-5
5
5
5
5
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Supplementary Table 1: PRISMA Checklist (Cont.)
Additional analyses

16

Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if
done, indicating which were pre-specified.

RESULTS
Study selection

17

Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons
for exclusions at each stage, ideally with a flow diagram.
For each study, present characteristics for which data were extracted (e.g., study size, PICOS,
follow-up period) and provide the citations.
Present data on risk of bias of each study and, if available, any outcome level assessment (see item
12).
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data
for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.

5-6
6,
Figure 1
6-7,
Table 1
Supplementary Table
1
Figures 2-3,
Supplementary
Figures 1-4
7-8,
Figures 2-3,
Supplementary
Figures 1-4
8, Supplementary
Figures 5-7
7-8,
Figures 2-3,
Supplementary
Figures 1-2,4

Study
characteristics
Risk of bias within
studies
Results of individual
studies

18

Synthesis of results

21

Present results of each meta-analysis done, including confidence intervals and measures of
consistency.

Risk of bias across
studies
Additional analysis

22

Present results of any assessment of risk of bias across studies (see Item 15).

23

Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression
[see Item 16]).

24

Summarize the main findings including the strength of evidence for each main outcome; consider
their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g.,
incomplete retrieval of identified research, reporting bias).
Provide a general interpretation of the results in the context of other evidence, and implications for
future research.

10-11

Describe sources of funding for the systematic review and other support (e.g., supply of data); role
of funders for the systematic review.

NA

DISCUSSION
Summary of
evidence
Limitations

19
20

25

Conclusions

26

FUNDING
Funding

27

8-10

11

Supplementary Table 2: Newcastle-Ottawa Scale Quality Assessment Scores
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Author
Bauer [27]
Bias [28]
Box [23]
Cattoir [22]
Felsenstein [41]
Forrest [30]
Forrest [29]
Forrest [31]
Frye [42]
Heil [32]
Holtzman [46]
Huang [26]
Lockwood [24]
Macvane [34]
Macvane [33]
Maslonka [44]
Na [21]
Nagel [35]
Neuberger [20]
Nguyen [47]
Pardo [36]
Perez [15]
Revolinski [37]
Roshdy [25]
Sango [38]
Sothoron [39]
Suzuki [19]
Walker [40]
Wang [18]

Selection
(max 4 stars)
****
****
****
****
****
****
****
****
****
****
****
****
****
****
****
****
****
****
****
****
****
****
****
****
****
****
****
****
****

Comparability
(max 2 stars)
**

**
*
**
**
**
**

**
**
**
**

**

Outcome
(max 3 stars)
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***
***

Total Score
9
7
7
9
8
7
9
7
9
7
9
9
7
7
7
7
7
7
9
9
9
9
7
7
7
7
7
9
7
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Supplementary Table 3. Risk of Bias Quality Assessments
Author
Beuving [17]
Ly [43]

Random sequence
generation
Low
High

Allocation
concealment
Low
High

Blinding of participants
and personnel
High
High

Blinding of outcome
assessment
High
High

Incomplete
outcome data
Low
Low

Selective
reporting
Low
Low

Other
bias
Unclear
High
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Supplementary Figure 1. Mortality with mRDT vs conventional testing in BSI among studies controlling for confounding.

Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; ASP, antimicrobial stewardship program; M-H,
Mantel-Haenszel method; CI, confidence interval.
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Supplementary Figure 2. Mortality with mRDT vs conventional testing by organism type in BSI among studies controlling for
confounding.

Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; M-H, Mantel-Haenszel method; CI, confidence
interval.
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Supplementary Figure 3. Time to effective therapy with mRDT vs conventional testing in BSI.

*Conference abstract. Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; IV, Inverse variance
method; CI, confidence interval.
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Supplementary Figure 4. Length of stay with mRDT vs conventional testing in BSI.

*Conference abstract. Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; LOS, length of stay; IV,
Inverse variance method; CI, confidence interval.
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Supplementary Figure 5. Funnel plot of included studies for mortality of mRDT vs conventional testing in BSI.

Abbreviations: mRDT, molecular rapid diagnostic testing; ASP, antimicrobial stewardship program; BSI, bloodstream infection; SE,
standard error; OR, odds ratio.
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Supplementary Figure 6. Funnel plot of included studies for time to appropriate therapy of mRDT vs conventional testing in BSI.

Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; SE, standard error; MD, mean difference.
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Supplementary Figure 7. Funnel plot of included studies for length of stay of mRDT vs conventional testing in BSI.

Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; SE, standard error; MD, mean difference.
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